Tiny Hoekstra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Tiny Hoekstra has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Muriel P. C. Grooteman
Department of Nephrology, Amsterdam UMC, location Vrije Universiteit Amsterdam , Amsterdam
2 shared publications - Peter J. Blankestijn
Department of Nephrology and Hypertension, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands
2 shared publications Akin Özyilmaz
Dialysis Centre Groningen, Groningen, The Netherlands
1 shared publication- Alexandre E. Voskuyl
Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Amsterdam, The Netherlands
1 shared publication - Brigit C. van Jaarsveld
Department of Nephrology, Amsterdam UMC location Vrije Universiteit Amsterdam, Research institute Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands
1 shared publication - Camiel L. M. de Roij van Zuijdewijn
Department of Nephrology, VU University Medical Center, Amsterdam, The Netherlands
1 shared publication
Latest Publications
- Open Access
- 8 February 2023
- Published by Elsevier in Joint Bone Spine
- Vol. 90 (4) , 105540
Traditional and disease-related cardiovascular risk factors in ANCA-associated vasculitis: A prospective, two-centre cohort study
- 8 February 2023
- Published by Elsevier in Joint Bone Spine
- Vol. 90 (4) , 105540
Open AccessTraditional and disease-related cardiovascular risk factors in ANCA-associated vasculitis: A prospective, two-centre cohort study
- Open Access
Long-term clinical parameters after switching to nocturnal haemodialysis: a Dutch propensity-score-matched cohort study comparing patients on nocturnal haemodialysis with patients on three-times-a-week haemodialysis/haemodiafiltration
Objectives Nocturnal haemodialysis (NHD), characterised by 8-hour sessions ≥3 times a week, is known to improve clinical parameters in the short term compared with conventional-schedule haemodialysis (HD), generally 3×3.5–4 hours a week. We studied long-term effects of NHD and used patients on conventional HD/haemodiafiltration (HDF) as controls. Design Four-year prospective follow-up of patients who switched to NHD; we compared patients with patients on HD/HDF using propensity score matching. Setting 28 Dutch dialysis centres. Participants We included 159 patients starting with NHD any time since 2004, aged 56.7±12.9 years, with median dialysis vintage 2.3 (0.9–5.1) years. We propensity-score matched 100 patients on NHD to 100 on HD/HDF. Primary and secondary outcome measures Control of hypertension (predialysis blood pressure, number of antihypertensives), phosphate (phosphate, number of phosphate binders), nutritional status and inflammation (albumin, C reactive protein and postdialysis weight) and anaemia (erythropoiesis-stimulating agent (ESA) resistance). Results Switching to NHD was associated with a non-significant reduction of antihypertensives compared with HD/HDF (OR Conclusions After switching to NHD, the lower need for antihypertensives, phosphate binders and ESA persists for at least 4 years. These sustained improvements in NHD contrast significantly with the course of these parameters during continued treatment with conventional-schedule HD and HDF. NHD provides an optimal form of dialysis, also suitable for patients expected to have a long waiting time for transplantation or those convicted to indefinite dialysis.
Open AccessLong-term clinical parameters after switching to nocturnal haemodialysis: a Dutch propensity-score-matched cohort study comparing patients on nocturnal haemodialysis with patients on three-times-a-week haemodialysis/haemodiafiltration
Objectives Nocturnal haemodialysis (NHD), characterised by 8-hour sessions ≥3 times a week, is known to improve clinical parameters in the short term compared with conventional-schedule haemodialysis (HD), generally 3×3.5–4 hours a week. We studied long-term effects of NHD and used patients on conventional HD/haemodiafiltration (HDF) as controls. Design Four-year prospective follow-up of patients who switched to NHD; we compared patients with patients on HD/HDF using propensity score matching. Setting 28 Dutch dialysis centres. Participants We included 159 patients starting with NHD any time since 2004, aged 56.7±12.9 years, with median dialysis vintage 2.3 (0.9–5.1) years. We propensity-score matched 100 patients on NHD to 100 on HD/HDF. Primary and secondary outcome measures Control of hypertension (predialysis blood pressure, number of antihypertensives), phosphate (phosphate, number of phosphate binders), nutritional status and inflammation (albumin, C reactive protein and postdialysis weight) and anaemia (erythropoiesis-stimulating agent (ESA) resistance). Results Switching to NHD was associated with a non-significant reduction of antihypertensives compared with HD/HDF (OR Conclusions After switching to NHD, the lower need for antihypertensives, phosphate binders and ESA persists for at least 4 years. These sustained improvements in NHD contrast significantly with the course of these parameters during continued treatment with conventional-schedule HD and HDF. NHD provides an optimal form of dialysis, also suitable for patients expected to have a long waiting time for transplantation or those convicted to indefinite dialysis.
- Open Access
- 1 May 2017
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 32 (suppl_3) , iii318
SP550LONG TERM CHANGES OF CARDIAC LEFT VENTRICULAR GEOMETRIC PATTERNS IN PATIENTS WITH END STAGE KIDNEY DISEASE
INTRODUCTION AND AIMS: Abnormal left ventricular (LV) geometry is common in patients with chronic kidney disease (CKD). While concentric LV hypertrophy (cLVH) predominates in non-dialysis CKD, eccentric LVH (eLVH) is most prevalent in end-stage kidney disease (ESKD). In these patients, the risk of sudden death is highest. So far, it is unknown whether and how LV characteristics change over time in ESKD.
- 1 May 2017
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 32 (suppl_3) , iii318
Open AccessSP550LONG TERM CHANGES OF CARDIAC LEFT VENTRICULAR GEOMETRIC PATTERNS IN PATIENTS WITH END STAGE KIDNEY DISEASE
INTRODUCTION AND AIMS: Abnormal left ventricular (LV) geometry is common in patients with chronic kidney disease (CKD). While concentric LV hypertrophy (cLVH) predominates in non-dialysis CKD, eccentric LVH (eLVH) is most prevalent in end-stage kidney disease (ESKD). In these patients, the risk of sudden death is highest. So far, it is unknown whether and how LV characteristics change over time in ESKD.
- 1 August 2002
- Published by Elsevier in Thrombosis Research
- Vol. 107 (3-4) , 115-119
The 4G/5G-polymorphism in the PAI-1 gene is not associated with markers of atherosclerosis in male smokers
- 1 August 2002
- Published by Elsevier in Thrombosis Research
- Vol. 107 (3-4) , 115-119
The 4G/5G-polymorphism in the PAI-1 gene is not associated with markers of atherosclerosis in male smokers